Transforming Lung Cancer Through Science
Welcome to Research Advances, LUNGevity’s quarterly e-newsletter with easy-to-read content that helps you stay current on the latest insights shaping lung cancer research and patient care.
In this issue, you will find exciting scientific discoveries presented at major conferences and a special editorial on the past, present, and future of lung cancer survival. We also spotlight innovative research and share an overview of a recent FDA approval that broadens treatment options for patients.
Recent Conferences
Science Conference Highlights
Key Discoveries Shaping the Future of Lung Cancer Care
The European Society for Medical Oncology’s (ESMO) annual meeting brings together thousands of researchers and clinicians from around the world to share breakthroughs in cancer science. This year’s meeting offered important insights into lung cancer biology, treatment strategies, and patient outcomes. Our recap breaks down the most meaningful advances and helps you stay up to date on the discoveries gaining momentum in the field.
Explore key topics discussed at the meeting:
- Progress in Treating Early Stage ALK+ NSCLC
- Building on the Benefits from EGFR TKIs
- HER2+ NSCLC: Options for Oral TKIs are Emerging
- Deeper Understanding of Emerging SCLC Treatments
- A Potential New Treatment for Squamous NSCLC
Immunotherapy’s Next Strategic Leap
Breakthroughs presented at the Society for Immunotherapy of Cancer’s (SITC) annual meeting highlight how rapidly immunotherapy is evolving. New insights into combination approaches, tumor–immune interactions, and next-generation targets are paving the way for more precise, durable responses for patients. Learn more about the future of immunotherapy in lung cancer.
Stay tuned for LUNGevity’s upcoming coverage of the annual meeting of the American Association for Cancer Research (AACR) to stay up to date on the latest innovations shaping lung cancer care.
Special Editorial
The State of Lung Cancer
Overall survival for all cancers combined in the United States has reached 70 percent for the first time, but this progress does not reflect the reality for most people diagnosed with lung cancer. In this editorial, Dr. Upal Basu Roy, Executive Director of LUNGevity Research, outlines where lung cancer survival stands today, recognizes meaningful gains, and shares his expert perspective on the steps needed to transform lung cancer into a curable disease.
Science Spotlight
Fighting Cancer Fiercely While Treating Patients Gently
Immunotherapy has transformed lung cancer care, but it can have serious side effects for some patients. This new blog spotlights Dr. Diane Tseng’s journey to reduce immunotherapy side effects while also increasing the effectiveness of treatment. Her research, supported by a Career Development Award from LUNGevity, is paving the way for a blood test to detect pneumonitis and improve immunotherapy.
Drug News
Recent FDA Approvals
LUNGevity celebrates recent treatment approvals for lung cancer that build on research from basic scientists and translational researchers to improve outcomes for many people living with this disease.
On November 19, the US Food and Drug Administration (FDA) announced the accelerated approval of sevabertinib to treat patients with advanced NSCLC with mutations in the HER2 gene.
Support Lifesaving Research
The Future of Lung Cancer Starts Here
LUNGevity is the largest nonprofit funder of lung cancer research. Each year we invest in cultivating the next generation of scientific talent and advancing high-impact lung cancer research. Since 2002, LUNGevity’s research program has awarded $55+ million in research grants to scientists conducting innovative lung cancer research. You can learn more about the exciting research we supported in 2025 and see the list of the grants we are offering in 2026.
Help Transform Lung Cancer
The impressive improvements we’ve seen in treating lung cancer over the last 30 years are the direct result of sustained research. You can help ensure that lung cancer research carries this tremendous momentum into the future.
Donate today to help LUNGevity transform lung cancer into a curable disease.
